Keywords: AstraZeneca, Rigel, Fostamatinib, Rheumatoid arthritis
AstraZeneca/Rigel’s fostamatinib shows positive response in rheumatoid arthritis in Ph IIb study
Article | 22 September 2010
Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) new oral syk inhibitor, fostamatinib (R788), in-licensed from US firm Rigel Pharmaceuticals ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
